Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants

Pediatric Infectious Disease Journal

Volumn 23, Issue 11, 2004, Pages 1008-1014

  Nurkka, Anu ^a   Joensuu, Jaana ^a   Henckaerts, Isabelle ^b   Peeters, Pascal ^b   Poolman, Jan ^b   Kilpi, Terhi ^a   Käyhty, Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Conjugate vaccine; Infants; Protein D; Streptococcus pneumoniae

Indexed keywords

BACTERIAL PROTEIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PROTEIN D; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; VACCINE;

ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG CONJUGATION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENZYME IMMUNOASSAY; FOLLOW UP; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; IRRITABILITY; MAJOR CLINICAL STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SIDE EFFECT; SINGLE BLIND PROCEDURE; STREPTOCOCCUS INFECTION; COMPARATIVE STUDY; FEMALE; FINLAND; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; MALE; METHODOLOGY; MULTICENTER STUDY; PHYSIOLOGY; SAFETY; VACCINATION;

ANTIBODIES, BACTERIAL; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; IMMUNITY; IMMUNIZATION SCHEDULE; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SAFETY; SINGLE-BLIND METHOD; VACCINATION; VACCINES, CONJUGATE;

EID: 14744267853     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000143640.03214.18     Document Type: Article

References (32)

1. Lee LH, Lee CJ, Frasch CE. Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control tests. Crit Rev Microbiol. 2002;28:27-41.
2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
3. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-361.
4. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
5. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
6. Sniadack DH, Schwartz B, Lipman H, et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children-implications for vaccine strategies. Pediatr Infect Dis J. 1995;14:503-510.
7. O'Dempsey TJ, McArdle TF, Lloyd-Evans N, et al. Pneumococcal disease among children in a rural area of west Africa. Pediatr Infect Dis J. 1996;15:431-437.
8. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100-121.
9. Wuorimaa T, Käyhty H. Current state of pneumococcal vaccines. Scand J Immunol. 2002;56:111-129.
10. Dagan R, Eskola J, Leclerc C, et al. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun. 1998;66:2093-2098.
11. Fattom A, Cho YH, Chu C, et al. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine. 1999;17:126-133.
12. Akkoyunlu M, Ruan M, Forsgren A. Distribution of protein D, an immunoglobulin D-binding protein, in Haemophilus strains. Infect Immun. 1991;59:1231-1238.
13. Gatchalian SR, Borja-Tabora C, Bermal NR, et al. A randomized, placebo-controlled study to evaluate the immunogenicity of an 11-valent pneumococcal protein D conjugate vaccine administered as primary vaccination to infants at 6, 10 and 14 weeks of age. In: 19th Annual Meeting of the European Society for Paediatric Infectious Diseases, 2001, Istanbul, Turkey.
14. Akkoyunlu M, Forsgren A. Local and systemic antibody levels against protein D of Haemophilus influenzae following immunization and infection in rats. APMIS. 1996;104:709-717.
15. Akkoyunlu M, Melhus Å, Capiau C, et al. Protective effect of protein D conjugated polyribosyl ribitol phosphate vaccines against Haemophilus influenzae type b in an experimental otitis media rat model: immunogenicity and protective potential of protein D of Haemophilus influenzae against H. influenzae infection [doctoral thesis]. Malmö, 1997.
16. Bakkaletz L, Holmes K, DeMaria T, et al. Parenteral immunization with a chimeric fimbrin peptide or with combinations of fimbrin and lipoprotein D or fimbrin and OMP P6 afford protection against nasopharyngeal colonization and otitis media induced by NTHi in a chinchilla model. In: Third Extraordinary International Symposium on Recent Advances in Otitis Media, 1997, Copenhagen, Denmark.
17. Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003;21:3265-3272.
18. World Health Organization Expert Committee on Biological Standardization: Pneumococcal Conjugate Vaccines. Recommendations for production and quality control of pneumococcal conjugate vaccines. Available at: http://www.who.int/ biologicals/Guidelines/Vaccines.htm.
19. Anderson EL, Kennedy DJ, Geldmacher KM, et al. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr. 1996; 128:649-653.
20. Nieminen T, Eskola J, Käyhty H. Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine. 1998;16:630-636.
21. Käyhty H, Åhman H, Rönnberg PR, et al. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis. 1995;172:1273-1278.
22. Åhman H, Käyhty H, Tamminen P, et al. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J. 1996;15: 134-139.
23. Arakere G, Lee AL, Frasch CE. Involvement of phospholipid end groups of group C Neisseria meningitidis and Haemophilus influenzae type b polysaccharides in association with isolated outer membranes and in immunoassays. J Bacteriol 1994;176:691-695.
24. Nurkka A, Åhman H, Korkeila M, et al. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20:25-33.
25. Wuorimaa T, Dagan R, Eskola J, et al. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr Infect Dis J. 2001;20:272-277.
26. Kilpi T, Åhman H, Jokinen J, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis. 2003;37: 1155-6114.
27. Nurkka A, Åhman H, Yaich M, et al. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine. 2001;20:194-201.
28. Dagan R, Melamed R, Zamir O, et al. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J. 1997;16:1053-1059.
29. Lee LH, Frasch CE, Falk LA, et al. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine. 2003;21:2199-2205.
30. Prymula R, Krizova P, Chrobok V, et al. A Czech multicenter prospective survey of bacterial acute otitis media in young children. In: 19th Annual Meeting of the European Society for Paediatric Infectious Diseases, 2001, Istanbul, Turkey.
31. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage: Advisory Committee on Immunization Practices. JAMA. 2002; 287:833-834.
32. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for the third and fourth dose. MMWR. 2004;53:177-178.